Compromised Immunologic Recovery in Patients Receiving Tipranavir/Ritonavir Coadministered With Tenofovir and Didanosine in Randomized Evaluation of Strategic Intervention in multidrug-reSistant patients with Tipranavir (RESIST) Studies

摘要

The evolution of drug-resistant HIV-1 is a major contributory factor in the development of virologic failure,1 and newer agents are needed to overcome cross-resistance to antiretrovirals (ARVs), including protease inhibitors (Pis).The nonpeptidic PI tipranavir (TPV) has potent in vitro activity against the majority of Pi-resistant HIV-1 strains.2 Low-dose ritonavir is coadministered with TPV (TPV/r) to ensure that therapeutic levels of TPV are achieved.3 The TPV/r combination has potent activity against HIV-1 in treatment-naive4 and treatment-experienced patients.